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were 7 associated procedures: 4 VSD closure, 2 balloon dilatation of aortic reco-
arctation and one main PA stenting. For PA band dilatation, 17 high pressure bal-
loons were used and 11 low pressure balloons (mean balloon diameter: 12mm).
Median RV/Ao pressure ratio dropped from 1 (± 0,3; 0,42-2,2) to 0,6 (± 0,3; 0,3-
1,2) and median RV to PA gradient dropped from 61 mmHg (± 31; 42-160) to 19
mmHg (±26; 12-83). Post intervention, mean saturation was 99% (93-100). When
looking at outcome, 23 patients had no further interventions, 1 patient needed 2
dilatations of PA band and 4 patients had surgery (1 double switch, 1 vicious PA
band removal, 1 in a context of severe RV dysfunction with tricuspid regurgitation
and 1 for VSD closure and main PA stent removal). One patient died of RV
failure after surgery and ventricular assistance.
Conclusion: Intervention on dilatable PA band is safe and carries good
results with definitive treatment in the majority of cases.
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Background: In CHD with RV volumetric or barometric overload, LV
shape is altered. Little is known about the accuracy in this population of left
ventricular (LV) volumes and ejection fraction (EF) measurement by standard
echocardiographic methods using geometrical assumption: Teicholz, biplane
Simpson and real-time 3D echocardiography (RT-3DE). Three-dimensional
knowledge-based reconstruction (3D-KR) derived from two-dimensional
echocardiographic imaging is a novel technique that has no geometrical
assumption. The aim of our study is to assess the accuracy of several echocar-
diographic methods for measuring LV volumes and EF compared to cardiac
magnetic resonance (CMR) measurements (gold standard) in this population.
Methods: 68 patients (mean age 13,3±4 years) with Congenital Heart Dis-
eases (CHD) involving the RV and referred for cardiac MRI, were included.
Among them, 13 patients had barometric overload, 37 patients had volumetric
overload, and 18 patients had mixed overload. Echocardiographic images acqui-
sition was performed using a standard ultrasound scanner linked to a Ventripoint
Medical Systems unit. Analyzed parameters were end-diastolic volume (EDV),
end-systolic volume (ESV), and LVEF measured by Teicholz, Simpson’s mod-
ified formula and RT-3DE (GE Vingmed QVG Auto-4D). The method of disks
was used for CMR LV volumes. Intra-observer, inter-observer, and inter-tech-
nique variability was assessed using intraclass correlation coefficient (CC),
Pearson’s CC, coefficients of variation, and Bland-Altman analysis.
Results: Feasibility was 98% for Teicholz Method and 3D-KR, 71% for
Simpson’s modified formula, and 73% for RT-3DE. We found globally poor
correlation and agreement for volumes and EF between the different methods
and MRI. The agreement was better when RV volumes were lower than
120ml/m² (and thus, LV shape was less altered).
Conclusions: LV volumes and EFs cannot be measured accurately by
echocardiography in patients with dilated right ventricles.
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Background: Residual abnormalities in cardiac structure and function pre-
dispose ACHD to late-onset heart failure and its complications. Therefore,
heart transplantation (HT) in ACHD is increasingly used.
Methods: Out of a multi-institutional (3 centers) series of 2257 HT from
1988 to 2012, 100 (4.4%) were performed in 97 ACHD (65 men). They
represented 45% of ACHD recipients in France at that time. We investigated
the role of temporal trends on profile and outcomes of ACHD recipients.
Trends were compared between 2 eras: era 1 (1988-2005, n=48) and era 2
(2006-2012, n=49).
Results: Mean age at the time of HT was 29.8 years. Forty-three patients
(44%) had univentricular physiology (1V). Severity of disease was catego-
rized in terms of initial diagnosis (according to classification of 32th ACC
Bethesda Conference): 74.2% had a great complexity cardiopathy while
21.7% had a moderate severity disease and 4.1% a simple CHD. In-hospital
mortality was high (34%).
Baseline characteristics did not differ significantly between the 2 eras. Era
2 recipients had less often right heart failure signs before HT. Their donors
were older. They were more likely to be hospitalized, supported by inotropes
and assist devices at the time of HT. The rate of 1V patients did not change
over time: 50% in era 1 vs 39% in era 2 (p=0.27). The distribution of severity
of disease changed significantly over time (p=0.048). The proportion of adult
recipients with CHD of great complexity was higher in era 2 than era 1
(respectively 81.6% and 66.7%). In fact, transposition of the great arteries
became the major provider of HT in adult in the recent era (30.6% in era 2 vs
8.3%, p=0.006), representing the only primary diagnosis whose proportion
increased significantly. Multivariable factors associated with increased in-hos-
pital mortality did not include transplant era.
Conclusion: Despite a worse baseline risk profile, and increasing com-
plexity of ACHD recipients in recent years, mortality after HT has not
increased.
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Background: Animal studies showed that levosimendan protects cardio-
myocytes against apoptotic cell death in acute viral myocarditis. In addition to
its inotropic properties, levosimendan seems to prevent the detrimental effects
of oxidative stress and to limit cardiomyocyte loss.
Aim: To analyze the outcome of children who received levosimendan for
acute or fulminant viral myocarditis. 
Patients and methods: Retrospective single center study covering the
period 2007- 2013. All children (<18 years) with viral myocarditis were
treated, in association with epinephrine and/or milrinone, with a 24-hours
infusion of levosimendan. Clinical, biological and echocardiographic evolu-
tions were analyzed.
Results: Between 2007 and 2013, 18 successive children were treated,
9 for acute myocarditis and 9 for fulminant myocarditis (according to the
international clinicopathological classification). Median age was 4 years (1.1-
11) and median weight was 15kg (10-40). BNP level significantly decreased
48 hours after the beginning of the infusion (4599ng/L [2698-9266] vs
1928ng/L [848-4557], p=0.05). No dialysis was necessary. Among the fulmi-
nant myocarditis group, 1 patient (11%) required early mechanical circulatory
support with a limitation of care due to severe neurologic complications.
13 patients (72%) recovered a LVEF >55% (100% for the acute myocarditis
group). 1 patient had heart transplantation 18 months later.
Conlusion: In our experience, levosimendan was efficient for the inotropic
support of acute and fulminant viral myocarditis. We believe that its cardio-
protective effect enabled us to limit the use of mechanical assistance (only
11% of the fulminant forms) and allowed a recovering of the cardiac function
for the majority of the patients. Although further clinical studies are needed to
confirm these data, levosimendan should be systematically considered for the
treatment of these critical patients.
